Drug Profile


Alternative Names: Khelline; Khellinum; KUVA; Visammin

Latest Information Update: 09 Nov 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ardeypharm; Loges; Nonindustrial source
  • Class Antiasthmatics; Bronchodilators; Ischaemic heart disorder therapies; Psoralens; Small molecules; Vasodilators
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Cardiovascular disorders
  • Discontinued Alopecia; Vitiligo

Most Recent Events

  • 05 Dec 2003 No development reported - Clinical-Phase-Unknown for Vitiligo in Bulgaria (Topical)
  • 05 Dec 2003 No development reported - Clinical-Phase-Unknown for Vitiligo in South Africa (Topical)
  • 22 Sep 2000 No-Development-Reported for Alopecia in Italy (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top